M&A Deal Summary |
|
---|---|
Date | 2023-10-23 |
Target | NAYA Biosciences |
Sector | Life Science |
Buyer(s) | Invo Bioscience |
Deal Type | Merger |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2007 |
Sector | Life Science |
Employees | 25 |
Revenue | 3M USD (2023) |
Invo Bioscience is a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. The company's primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Its flagship product is INVOcell, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Invo Bioscience was founded in 2007 and is based in Sarasota, Florida.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 1 of 1 |
Type (Merger) | 1 of 1 |
State (Florida) | 1 of 1 |
Country (United States) | 2 of 2 |
Year (2023) | 2 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-03-20 |
Wisconsin Fertility Institute
Middleton, Wisconsin, United States Wisconsin Fertility Institute provides care based on the latest medical evidence for a wide range of conditions, including all aspects of infertility, women's hormonal problems, abnormal female structural anatomy, and complex gynecologic surgery. Its services include both traditional medical interventions as well as complementary and alternative medical approaches: hormone treatments, fertility surgery, artificial insemination, in-vitro fertilization, donor sperm and oocytes, surrogacy and gestational carriers, and semen and ovarian tissue cryopreservation. Wisconsin Fertility Institute is based in Middleton, Wisconsin. |
Buy | $10M |